Cyclin Dependent Kinase Like 5 Cdkl5 Deficiency Disorder Epidemiology Forecast

DelveInsight's 'Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Understanding

CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004.


The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development.


The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two X’s, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females.

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Perspective by DelveInsight

The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Detailed Epidemiology Segmentation

  • In the 7MM, the total prevalent population of CDD was estimated to be 16,397 cases in 2017.
  • The total diagnosed prevalent population of CDD in the seven major markets was 3,584 in 2017, which is expected to increase in the forecast period
  • In 2017, the total diagnosed prevalence of CDD in the United States was 208 in males and 1,315 in females
  • There are several types of clinical characteristics of CDD, among which, mainly eight types of characteristics are frequently observed. As per the estimates 1,234, 716, 1,142, 1,218, 1,317, 1,080, 976, 1,295, patients were affected by epileptic spasms, hypsarrhythmia, cortical visual impairment, hand stereotypies, gastrointestinal symptoms, constipation, reflux, and sleep difficulties in 2017.


Scope of the Report

  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Report and Model provide an overview of the risk factors and global trends of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
  • The report provides the segmentation of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology


Report Highlights

  • Eleven-Year Forecast of CDD
  • 7MM Coverage
  • Prevalence of CDD in 7MM
  • Diagnosed Prevalence of CDD in 7MM
  • Gender-specific Diagnosed Prevalence of CDD
  • Clinical Characteristics of CDD


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?
  • What are the key findings pertaining to the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?
  • What are the currently available treatments of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?


Reasons to buy

  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market
  • Quantify patient populations in the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder therapeutics in each of the markets covered
  • Understand the magnitude of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder population by its epidemiology
  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment and Management

6.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

List of Tables:

Table 1: Summary of CDKL5 Deficiency Disorder (CDD), Epidemiology, and Key Events (2017–2030)

Table 2: Symptoms of CDD

Table 3: Common clinical characteristics and proposed minimal diagnostic criteria

Table 4: Total Prevalent Population of CDD in the 7MM (2017–2030)

Table 5: Total Diagnosed Prevalent Population of CDD in the 7MM (2017–2030)

Table 6: Prevalence of CDD in the United States (2017–2030)

Table 7: Diagnosed Prevalence of CDD in the United States (2017–2030)

Table 8: Gender-specific Diagnosed Prevalence of CDD in the United States (2017–2030)

Table 9: Clinical Characteristics of CDD in the United States (2017–2030)

Table 10: Prevalence of CDD in Germany (2017–2030)

Table 11: Diagnosed Prevalence of CDD in Germany (2017–2030)

Table 12: Gender-specific Diagnosed Prevalence of CDD in Germany (2017–2030)

Table 13: Clinical Characteristics of CDD in Germany (2017–2030)

Table 14: Prevalence of CDD in France (2017–2030)

Table 15: Diagnosed Prevalence of CDD in France (2017–2030)

Table 16: Gender-specific Diagnosed Prevalence of CDD in France (2017–2030)

Table 17: Clinical Characteristics of CDD in France (2017–2030)

Table 18: Prevalence of CDD in Italy (2017–2030)

Table 19: Diagnosed Prevalence of CDD in Italy (2017–2030)

Table 20: Gender-specific Diagnosed Prevalence of CDD in Italy (2017–2030)

Table 21: Clinical Characteristics of CDD in Italy (2017–2030)

Table 22: Prevalence of CDD in Spain (2017–2030)

Table 23: Diagnosed Prevalence of CDD in Spain (2017–2030)

Table 24: Gender-specific Diagnosed Prevalence of CDD in Spain (2017–2030)

Table 25: Clinical Characteristics of CDD in Spain (2017–2030)

Table 26: Prevalence of CDD in the United Kingdom (2017–2030)

Table 27: Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Table 28: Gender-specific Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Table 29: Clinical Characteristics of CDD in the United Kingdom (2017–2030)

Table 30: Prevalence of CDD in Japan (2017–2030)

Table 31: Diagnosed Prevalence of CDD in Japan (2017–2030)

Table 32: Gender-specific Diagnosed Prevalence of CDD in Japan (2017–2030)

Table 33: Clinical Characteristics of CDD in Japan (2017–2030)


List of Figures:

Figure 1: CDKL5 Deficiency Disorder (CDD) SWOT Analysis

Figure 2: Location of CDKL5 gene

Figure 3: X linked dominant inheritance

Figure 4: A schematic of the CDKL5 protein with variants from individuals with CDD evaluated in the CDKL5 Centers of Excellence (COEs)

Figure 5: Physiological CDKL5 substrates control cytoskeletal function.

Figure 6: Total Prevalent Patient Population of CDD in the 7MM (2017–2030)

Figure 7: Total Diagnosed Prevalent Patient Population of CDD in the 7MM (2017–2030)

Figure 8: Prevalence of CDD in the United States (2017–2030)

Figure 9: Diagnosed Prevalence of CDD in the United States (2017–2030)

Figure 10: Gender-specific Diagnosed Prevalence of CDD in the United States (2017–2030)

Figure 11: Clinical Characteristics of CDD in the United States (2017–2030)

Figure 12: Prevalence of CDD in Germany (2017–2030)

Figure 13: Diagnosed Prevalence of CDD in Germany (2017–2030)

Figure 14: Gender-specific Diagnosed Prevalence of CDD in Germany (2017–2030)

Figure 15: Clinical Characteristics of CDD in Germany (2017–2030)

Figure 16: Prevalence of CDD in France (2017–2030)

Figure 17: Diagnosed Prevalence of CDD in France (2017–2030)

Figure 18: Gender-specific Diagnosed Prevalence of CDD in France (2017–2030)

Figure 19: Clinical Characteristics of CDD in France (2017–2030)

Figure 20: Prevalence of CDD in Italy (2017–2030)

Figure 21: Diagnosed Prevalence of CDD in Italy (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalence of CDD in Italy (2017–2030)

Figure 23: Clinical Characteristics of CDD in Italy (2017–2030)

Figure 24: Prevalence of CDD in Spain (2017–2030)

Figure 25: Diagnosed Prevalence of CDD in Spain (2017–2030)

Figure 26: Gender-specific Diagnosed Prevalence of CDD in Spain (2017–2030)

Figure 27: Clinical Characteristics of CDD in Spain (2017–2030)

Figure 28: Prevalence of CDD in the United Kingdom (2017–2030)

Figure 29: Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Figure 30: Gender-specific Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Figure 31: Clinical Characteristics of CDD in the United Kingdom(2017–2030)

Figure 32: Prevalence of CDD in Japan (2017–2030)

Figure 33: Diagnosed Prevalence of CDD in Japan (2017–2030)

Figure 34: Gender-specific Diagnosed Prevalence of CDD in Japan (2017–2030)

Figure 35: Clinical Characteristics of CDD in Japan (2017–2030)

  • Tags:
  • Cyclin-Dependent Kinase-Like 5 (CDK...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...
  • Cyclin-Dependent Kinase-Like 5 (CD...

Forward to Friend

Need A Quote